Identification and validation of an explainable screening model of college students’ mental health with therapeutic strategy implications.

Publication date: Jul 21, 2026

Mental health issues, especially depressive symptoms, among young adults represent a public health challenge. Conventional psychological assessment tools have limited sensitivity and specificity for identifying individuals at risk. This study aims to develop an explainable machine learning-based model to stratify concurrent depression risk in young adults. This study included 100,257 college students and collected mental health variables including depression, anxiety, resilience, parent-child relationship, and duration of mobile phone usage. The screening capabilities of 13 machine learning algorithms were systematically evaluated and compared. The SHapley Additive exPlanations (SHAP) framework was employed for the interpretability of the final model. The median scores for parent-child relationship, resilience, anxiety, and mobile phone usage time was 42. 0, 28. 0, 1. 0 and 28. 0, respectively. Among the 13 machine learning algorithms, the XGBoost model demonstrated superior performance. The final multivariate screening model achieved an area under the curve (AUC) of 0. 887, a sensitivity of 0. 787, a specificity of 0. 830, and an accuracy of 0. 816 in classifying young adults’ concurrent depression risk. The SHAP analysis showed the importance of each variable: anxiety (2. 303) > resilience (0. 774) > parent-child relationship (0. 708) > mobile phone usage time (0. 411). The final multivariate model exhibited stable performance during cross-validation (AUC = 0. 885 +/- 0. 032), significantly better than the single-variable model (P 

Open Access PDF

Concepts Keywords
Adults College students
College Interpretability analysis
Depressive Machine learning
Mobile Mental health
Screening model

Semantics

Type Source Name
disease MESH included
disease MESH anxiety
drug DRUGBANK Tropicamide
pathway REACTOME Reproduction
disease MESH Drug Dependence
drug DRUGBANK Aspartame
drug DRUGBANK Coenzyme M
disease MESH ext
disease MESH pku
disease MESH COVID 19
disease MESH mental disorders
drug DRUGBANK Flunarizine
disease MESH CPA
disease MESH CES
disease MESH Generalized Anxiety Disorder
drug DRUGBANK Dichloroacetic Acid
disease MESH ibm
drug DRUGBANK Saquinavir
disease MESH face
disease MESH inflammation
drug DRUGBANK Sirolimus
pathway KEGG mTOR signaling pathway
disease MESH brain diseases
disease MESH Plan
disease MESH MDD
drug DRUGBANK Guanosine
disease MESH Dis
drug DRUGBANK Trestolone
disease MESH Affective Disorders
disease MESH depressive disorders
drug DRUGBANK Carboxyamidotriazole
disease MESH autism
disease MESH HCI
disease MESH Burns
disease MESH metastases
disease MESH XFS
pathway REACTOME Metabolism
disease MESH metabolic disease
drug DRUGBANK Amino acids
disease MESH trauma
disease MESH MAE
drug DRUGBANK Isoxaflutole

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *